Home

Products

Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.

AB-25E9 – inhibition of bone degradation

Alethia is developing a first-in-class bone antiresorptive for the treatment of bone loss in acute disorders such a hypercalcemia of malignancy, bone and cartilage loss in inflammatory disorders and severe osteoporosis. Read more about AB-25E9

AB-3A4 – invasive carcinomas

Alethia is developing a therapeutic monoclonal antibody for the treatment of ovarian cancer and other invasive carcinomas such as triple-negative breast tumors and renal cancer. AB-3A4 is an IgG1 monoclonal antibody against KAAG-1, a cell-surface protein involved in tumor invasion. Read more about AB-3A4

AB-16B5 – inhibition of EMT

Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5

News

  • January 20, 2014 Alethia Biotherapeutics announces publication of data about its bone antiresorptive program published in the Journal of Biological Chemistry: "Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic b...
  • October 9, 2013 Alethia Biotherapeutics Announces the Issuance of a Patent for the Use of Anti-Siglec-15 Antibodies Alethia PR 131009 EN...
  • May 29, 2013 Alethia Biotherapeutics Announce Entry into Licensing and Research Agreements for its Inhibitor of EMT with IBC Generium Alethia 130529 EN...

Events

  • October 26 - 29, 2014 Alethia Biotherapeutics to be part of the¬†World ADC San Diego 2014. Dr. Gilles Tremblay will be in attendance....
  • October 8 - 9, 2014 Alethia Biotherapeutics to present at the 12th Annual Discovery on Target conference at the Westin Boston Waterfront, Boston, MA. Dr. Mario Filion, Chief Scientific Officer, will be a speaker during the Antibodies Against Membrane Protein Targets session ...
  • September 12 - 15, 2014 Alethia Biotherapeutics to be part of the ASBMR Annual Meeting at the George R. Brown Convention Center, Houton, Texas. Drs. ¬†Anna Moriatis and Gilles Tremblay will be in attendance....